Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Terns Pharmaceuticals Inc
(NQ:
TERN
)
9.770
+0.360 (+3.83%)
Streaming Delayed Price
Updated: 2:30 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Terns Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
May 03, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
April 29, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
April 10, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
TERN Stock Earnings: Terns Pharma Meets EPS for Q4 2023
March 14, 2024
TERN stock results show that Terns Pharma met analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Recap: Terns Pharma Q3 Earnings
November 14, 2023
Via
Benzinga
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
March 25, 2024
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
March 21, 2024
Via
Benzinga
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
March 17, 2024
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Via
The Motley Fool
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
March 14, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
March 11, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
March 07, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
February 27, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 09, 2024
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results.
Via
Benzinga
Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
February 07, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
February 07, 2024
Proven Industry Executive Brings More Than 25 Years of Leadership Experience
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
February 02, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
January 03, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
December 05, 2023
As of Dec. 5, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
SAIC Reports Q3 Results, Joins Uber, Wallbox And Other Big Stocks Moving Higher On Monday
December 04, 2023
U.S. stocks traded lower, with the Dow Jones index falling more than 100 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 04, 2023
Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20...
Via
Benzinga
Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
November 29, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer
November 27, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates
November 14, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023
November 13, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
November 09, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
November 03, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity
November 02, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals to Participate in Upcoming Investor Conferences
October 19, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia
October 16, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.